Updated:
Essentialis
Developer of rare metabolic diseases therapeutics. The company focuses on developing medicines for rare metabolic diseases with high mortality and...
Essentialis
Developer of rare metabolic diseases therapeutics. The company focuses on developing medicines for rare metabolic diseases with high mortality and cardiovascular risk. Its lead product targets the ATP-sensitive potassium channel, a metabolically-regulated membrane protein.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Carlsbad
Corporate office
Carlsbad, CA, United States
Additional offices
Palo Alto, CA · San Diego, CA · Redwood City, CA · San Francisco, CA · Denver, CO · Oslo, Norway · Kowloon, Hong Kong
Frequently asked questions
What is Essentialis's known track record or portfolio?
No specific portfolio companies, realized exits, or fund-level performance data have been publicly attributed to Essentialis. The firm does not appear to disclose its investments through press releases, regulatory filings that surface in commercial databases, or standard industry reporting. Allocators considering engagement should expect to request this information directly during due diligence.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: